Empery Alleges Critical Clinical Trial Misrepresentations by Seelos Therapeutics
Empery Asset Management, LP (“Empery”) wishes to inform shareholders of Seelos Therapeutics, Inc (the “Company” or “Seelos”) that Empery transmitted a letter to management and the board of directors of Seelos alleging material misrepresentations that the Company’s CEO made regarding the SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide (the “Trial”).
- Empery Asset Management, LP (“Empery”) wishes to inform shareholders of Seelos Therapeutics, Inc (the “Company” or “Seelos”) that Empery transmitted a letter to management and the board of directors of Seelos alleging material misrepresentations that the Company’s CEO made regarding the SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide (the “Trial”).
- The Company represented to Empery that its March 2023 financing would be sufficient to complete the Trial as publicly disclosed.
- Empery believes that the Trial was doomed because the Company did not seek the appropriate funds to run a properly powered Trial.
- Currently, Empery believes that management's and the board's misconduct have significantly damaged Empery, and it is seeking recovery from Seelos.